<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714918</url>
  </required_header>
  <id_info>
    <org_study_id>CRISS-MBD</org_study_id>
    <nct_id>NCT04714918</nct_id>
  </id_info>
  <brief_title>Chinese CKD-MBD Prevalence Survey (CRISS-MBD)</brief_title>
  <official_title>Chinese Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Prevalence Survey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Limeng Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center cross sectional epidemiological study. The purpose of this study is to&#xD;
      investigate the prevalence of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) in&#xD;
      Chinese population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of Chronic Kidney Disease (CKD) in Chinese population is over 10% and&#xD;
      increasing rapidly. Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) is a&#xD;
      constellation of conditions secondary to CKD, including 1) metabolic disorders of calcium,&#xD;
      phosphorus and Parathyroid Hormone (PTH), 2) bone diseases and 3) calcifications in blood&#xD;
      vessels and soft tissues. CKD-MBD could increase the risks of cardiovascular diseases and&#xD;
      bone fracture and overall mortality. However, the data of prevalence of CKD-MBD in Chinese&#xD;
      population with different CKD stages is lacking. This is a multi-center cross sectional&#xD;
      epidemiological study. The purpose of this study is to investigate the prevalence of Chronic&#xD;
      Kidney Disease-Mineral and Bone Disorder (CKD-MBD) in Chinese population.This is a&#xD;
      multi-center cross sectional epidemiological study. The purpose of this study is to&#xD;
      investigate the prevalence of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) in&#xD;
      Chinese population. A questionnaire was designed to collect the information of demographic&#xD;
      data, medical history, laboratory test results and medications from the patients. Multistage&#xD;
      stratified cluster sampling method will be used. Based on the sample size estimation, a total&#xD;
      of 14-28 tertiary hospitals and 42-56 level II hospitals distributed in seven different&#xD;
      geographic regions across China will be included. At least 9863 subjects will be enrolled.&#xD;
      The primary outcome is the prevalence of CKD-MBD, including the prevalence of hypocalcemia,&#xD;
      hyperphosphatemia and secondary hyperparathyroidism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2020</start_date>
  <completion_date type="Anticipated">November 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The prevalence of hyperphosphatemia</measure>
    <time_frame>At the end of the enrollment.</time_frame>
    <description>The prevalence of hyperphosphatemia (serum phosphate &gt; 1.45mmol/L) in the whole study population and in participants with different CKD stages.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The prevalence of hypocalcemia</measure>
    <time_frame>At the end of the enrollment.</time_frame>
    <description>The prevalence of hypocalcemia (serum calcium &lt; 2.13mmol/L) in the whole study population and in participants with different CKD stages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The prevalence of secondary hyperparathyroidism</measure>
    <time_frame>At the end of the enrollment.</time_frame>
    <description>The prevalence of secondary hyperparathyroidism (iPTH &gt; 300pg/ml) in the whole study population and in participants with different CKD stages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The prevalence of hypercalcemia</measure>
    <time_frame>At the end of the enrollment.</time_frame>
    <description>The prevalence of hypercalcemia (serum calcium &gt; 2.70mmol/L) in the whole study population and in participants with different CKD stages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The prevalence of bone fracture</measure>
    <time_frame>At the end of the enrollment.</time_frame>
    <description>The prevalence of bone fracture in the whole study population and in participants with different CKD stages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The prevalence of vascular calcification</measure>
    <time_frame>At the end of the enrollment.</time_frame>
    <description>The prevalence of vascular calcification identified by CT scan or ultrasound in the whole study population and in participants with different CKD stages.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">9863</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Chronic Kidney Disease-Mineral and Bone Disorder</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This study plans to include hospitalized CKD patients who are not on dialysis and dialysis&#xD;
        patients followed regularly in HD centers or PD centers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Kidney damage for â‰¥ 3 months, and one of the following criteria:&#xD;
&#xD;
               1. Glomerular filtration rate (GFR) &lt;60 mL/min/1.73m2 for 3 months or more,&#xD;
                  irrespective of cause.&#xD;
&#xD;
               2. proteinuria (&gt;30 mg of urinary albumin excretion per gram of urinary creatinine,&#xD;
                  &gt; 50 mg of urinary protein excretion per gram of urinary creatinine, &gt;1+ for&#xD;
                  proteinuria in dipstick, &gt; 0.3g of 24 hour urine protein)&#xD;
&#xD;
               3. structural renal abnormalities&#xD;
&#xD;
          -  hospitalized patients not on dialysis or dialysis patients followed regularly in&#xD;
             Hemodialysis centers or Peritoneal Dialysis centers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no available test results within 3 months prior to this study&#xD;
&#xD;
          -  no available information of medication or past medical history&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Limeng Chen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng Xia, MD</last_name>
    <phone>+86-13811684903</phone>
    <email>7-xp@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaohong Fan, MD</last_name>
    <phone>+86-13811559757</phone>
    <email>fxhcmu@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Xia, MD</last_name>
      <phone>+86-1381168403</phone>
      <email>7-xp@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaohong Fan, MD</last_name>
      <phone>+86-13811559757</phone>
      <email>fxhcmu@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Limeng Chen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peng Xia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaohong Fan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enhao Yang, MD, PhD</last_name>
      <phone>+86-13983836679</phone>
      <email>379239336@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Wen Wen, MSc</last_name>
      <phone>+86-15683168986</phone>
      <email>86140771@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hua Gan, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaogang Du, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enhao Yang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wen Wen, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weihua Liu, MM</last_name>
      <phone>13599394882</phone>
      <email>305855638@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Miao Lin, MD</last_name>
      <phone>13506993517</phone>
      <email>10151246@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Fuyuan Hong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinbin Wu, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li Zhang, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yiping Ruan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meizhu Gao, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fuxin Dong, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Seventh Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhihua Zheng, MD</last_name>
      <phone>+86-13922298682</phone>
      <email>zhihuazheng@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Jinhong Li, MD</last_name>
      <phone>+86-15712078292</phone>
      <email>lijinhong0414@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zhihua Zheng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinhong Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yueyu Zheng, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lanyue Zhang, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cuifang Li, MM</last_name>
      <phone>15274987725</phone>
      <email>810314451@qq.com</email>
    </contact>
    <investigator>
      <last_name>Hui Xu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cuifang Li, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinwang Zhu, MD, PhD</last_name>
      <phone>+86-13804056472</phone>
      <email>zhuxinwang_cmu@126.com</email>
    </contact>
    <investigator>
      <last_name>Li Yao, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xinwang Zhu, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Ningxia Hui Autonomous Region</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yali Zheng, MD</last_name>
      <phone>13639505291</phone>
      <email>424570556@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Li Cao, MM</last_name>
      <phone>13895099239</phone>
      <email>nxcaoli@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yali Zheng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li Cao, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danna Ma, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guoqing Zhang, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jing E, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiumei Zhang, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yanping Han, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bo Li, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kaixiang Li, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yongcai Gao, BM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinping Yao, BM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lurong Zou, BM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Feifei Luo, BM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Xinjiang Uygur Autonomous Region</name>
      <address>
        <city>ÃœrÃ¼mqi</city>
        <state>Xinjiang</state>
        <zip>830001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xueqin Zhang, MM</last_name>
      <phone>+86-15899197875</phone>
      <email>806593091@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Jing Zhuang, MM</last_name>
      <phone>+86-13659928280</phone>
      <email>2098602833@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chen Lu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shiru Xu, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adila Abulizi, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hui Luo, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jing Zhuang, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xueqin Zhang, MM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lijun Mou, MD, PhD</last_name>
      <phone>+86-13757164624</phone>
      <email>tiantangmou@126.com</email>
    </contact>
    <investigator>
      <last_name>Lijun Mou, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ying Hu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Zhou C, Wang F, Wang JW, Zhang LX, Zhao MH. Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease. Chin Med J (Engl). 2016 Oct 5;129(19):2275-80. doi: 10.4103/0366-6999.190678.</citation>
    <PMID>27647184</PMID>
  </results_reference>
  <results_reference>
    <citation>Kong X, Zhang L, Zhang L, Chen N, Gu Y, Yu X, Liu W, Chen J, Peng L, Yuan W, Wu H, Chen W, Fan M, He L, Ding F, Chen X, Xiong Z, Zhang J, Jia Q, Shi W, Xing C, Tang X, Hou F, Shu G, Mei C, Wang L, Xu D, Ni Z, Zuo L, Wang M, Wang H. Mineral and bone disorder in Chinese dialysis patients: a multicenter study. BMC Nephrol. 2012 Sep 21;13:116. doi: 10.1186/1471-2369-13-116.</citation>
    <PMID>22994525</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Limeng Chen</investigator_full_name>
    <investigator_title>Deputy Director, Department of Nephrology</investigator_title>
  </responsible_party>
  <keyword>Chronic Kidney Diseases</keyword>
  <keyword>Chronic Kidney Disease-Mineral and Bone Disorder</keyword>
  <keyword>Hypocalcemia</keyword>
  <keyword>Hyperphosphatemia</keyword>
  <keyword>Secondary Hyperparathyroidism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Chronic Kidney Disease-Mineral and Bone Disorder</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>To comply with laws in China, local regulations and hospital policy, IPD sharing might be restricted.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

